Medication info
Hirus Tablet (Vildagliptin)

Hirus Tablet (Vildagliptin)

Prescription medicationTabletOral
Ingredient · strength
Vildagliptin›50mg / 1 tablet
Manufacturer / importer
Korea United Pharmaceutical Co., Ltd.
Appearance
Round tablet that is white to pale yellow in color
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Active

MFDS item code 202200168 · Approved 2022.01.10 · Insurance code 644309670

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine may be administered as monotherapy, or in combination with metformin in patients with no prior experience of antidiabetic drug treatment, at a dose of 50mg once daily in the morning or 100mg daily, divided into 50mg twice daily in the morning and evening. When this medicine is administered in combination with metformin or a thiazolidinedione in patients whose blood glucose is not adequately controlled with metformin or thiazolidinedione monotherapy, the recommended dose is 100mg daily, divided into 50mg twice daily in the morning and evening. When this medicine is administered in combination with a sulfonylurea in patients whose blood glucose is not adequately controlled with sulfonylurea monotherapy, the recommended dose is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. When this medicine is administered as triple therapy in combination with a sulfonylurea and metformin in patients whose blood glucose is not adequately controlled with combination therapy of a sulfonylurea and metformin, the recommended dose is 100mg daily, divided into 50mg twice daily in the morning and evening. When this medicine is administered in combination with insulin (insulin alone or with metformin) in patients whose blood glucose is not adequately controlled with insulin therapy, the recommended dose is 100mg daily, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food, and doses exceeding 100mg daily are not recommended. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember, and take the next dose at the usual time. If you remember close to the time of the next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with renal impairment Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. Patients with moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 2) under “3. General Precautions” in Precautions for Use.

Ingredients

Manufacturer
Korea United Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Abnormal blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used alone or in combination with diet and exercise for the treatment of patients with type 2 diabetes to improve blood sugar control.

How to take

Adult dose

This medicine may be administered as monotherapy, or in combination with metformin in patients with no prior experience of antidiabetic drug treatment, at a dose of 50mg once daily in the morning or 100mg daily, divided into 50mg twice daily in the morning and evening. When this medicine is administered in combination with metformin or a thiazolidinedione in patients whose blood glucose is not adequately controlled with metformin or thiazolidinedione monotherapy, the recommended dose is 100mg daily, divided into 50mg twice daily in the morning and evening. When this medicine is administered in combination with a sulfonylurea in patients whose blood glucose is not adequately controlled with sulfonylurea monotherapy, the recommended dose is 50mg once daily in the morning. In this patient group, vildagliptin 100mg once daily was not more effective than 50mg once daily. When this medicine is administered as triple therapy in combination with a sulfonylurea and metformin in patients whose blood glucose is not adequately controlled with combination therapy of a sulfonylurea and metformin, the recommended dose is 100mg daily, divided into 50mg twice daily in the morning and evening. When this medicine is administered in combination with insulin (insulin alone or with metformin) in patients whose blood glucose is not adequately controlled with insulin therapy, the recommended dose is 100mg daily, divided into 50mg twice daily in the morning and evening. This medicine may be taken with or without food, and doses exceeding 100mg daily are not recommended. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. If you forget to take this medicine, take it as soon as you remember, and take the next dose at the usual time. If you remember close to the time of the next dose, skip the missed dose. Do not take a double dose at one time to make up for a missed dose. Patients with hepatic impairment This medicine is not recommended for patients with hepatic impairment whose ALT or AST levels exceed 2.5 times the upper limit of normal before treatment. Patients with renal impairment Patients with mild renal impairment (creatinine clearance ≥50mL/min): No dose adjustment is necessary. Patients with moderate or severe renal impairment or end-stage renal disease (ESRD): A dose of 50mg once daily is recommended. (See section 2) under “3. General Precautions” in Precautions for Use.

Precautions

This medication should not be used by patients who are allergic to the active ingredient or any other components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Since this medication contains lactose, it should not be used in patients with lactose intolerance or genetic lactose-related diseases. During treatment with this medication, liver dysfunction may rarely occur; therefore, regular liver function tests should be conducted before and during use. If liver enzyme levels rise more than three times the normal level or if symptoms of jaundice appear, discontinue use of this medication. Use is not recommended in patients with severe heart failure, as it may worsen heart failure symptoms, and caution is advised. This medication carries a risk of acute pancreatitis; therefore, if symptoms of pancreatitis occur, discontinue use immediately and consult a healthcare professional. When used in combination with sulfonylureas or other medications that may cause hypoglycemia, the risk of hypoglycemia may increase, and dosage adjustments may be needed. If symptoms such as dizziness occur while taking this medication, avoid driving or operating machinery. If severe joint pain or skin abnormalities such as blisters or ulcers occur, notify a healthcare professional immediately and discontinue this medication. It is safe not to use this medication in pregnant or breastfeeding women, and it is not recommended for children and adolescents under 18 years of age. There is no specific antidote for overdose; therefore, symptomatic supportive treatment should be initiated, and this medication cannot be removed by hemodialysis. Keep out of reach of children and avoid transferring to other containers.

Side effects

  • Hepatitis
  • liver dysfunction
  • elevated transaminase levels
  • angioedema
  • tremor
  • headache
  • dizziness
  • fatigue
  • nausea
  • hypoglycemia
Show 64 more
  • pharyngitis
  • asthenia
  • constipation
  • weight gain
  • peripheral edema
  • gastroesophageal reflux
  • diarrhea
  • bloating
  • chills
  • decreased blood sugar
  • hyperhidrosis
  • pancreatitis
  • urticaria
  • blisters
  • exfoliative skin lesions
  • severe and debilitating arthralgia
  • skin vasculitis
  • cholecystitis
  • upper respiratory tract infection
  • acute myocardial infarction
  • nodal arrhythmia
  • acute cholecystitis
  • pneumothorax
  • cholelithiasis
  • femoral fracture
  • peripheral artery occlusive disease
  • supraventricular tachycardia
  • congestive heart failure
  • gastric ulcer
  • gastric cancer
  • increased INR
  • appendicitis
  • pulmonary edema
  • vertigo
  • chest discomfort
  • dyspnea
  • cough
  • dyspepsia
  • drowsiness
  • itching
  • dry mouth
  • vomiting
  • insomnia
  • renal impairment
  • lip blisters
  • hunger
  • sensory loss
  • spinal stenosis
  • abdominal pain
  • gastroenteritis
  • gastritis
  • gastric ulcer
  • belching
  • fatty liver
  • hyperkalemia
  • hypertriglyceridemia
  • heart failure
  • cardiomyopathy
  • angina
  • cardiac arrest
  • renal cyst
  • lung cancer
  • leg pain
  • increased C-reactive protein

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Round tablet that is white to pale yellow in color

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.